Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00152425
Status:
COMPLETED
Last Update Posted:
2013-09-09
First Post:
2005-09-07
Brief Title:
Study to Test the Effect of CDP870 in the Treatment of Crohns Disease Over 26 Weeks Comparing CDP870 to a Dummy Drug Placebo Following 3 Doses of Active Drug CDP870
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase III Multi-national Multi-centre Double-blind Placebo-controlled Parallel Group 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc Dosed 4-weekly From Weeks 8 to 24 in the Treatment of Patients With Active Crohns Disease Who Have Responded to Open Induction Therapy Dosed at Weeks 0 2 and 4 With CDP870
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 26 week maintenance study of CDP870 in Crohns disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None